Mariot et al. (2015) demonstrated that levels of FAT1 are lower in muscles that are affected at early stages of FSHD progression than in healthy muscles or muscles that are affected later in time. This evidence concerns the gene FAT1 and facioscapulohumeral muscular dystrophy.